^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FAT1 (FAT atypical cadherin 1)

    i
    Other names: Cadherin ME5, CDHR8, HFat1, ME5, FAT Tumor Suppressor 1, FAT Tumor Suppressor Homolog 1, FAT Tumor Suppressor, CDHF7, Cadherin Family Member 7, FAT1, FAT Atypical Cadherin 1, Cadherin-Related Tumor Suppressor Homolog, Cadherin-Related Family Member 8
    2d
    Gingivobuccal Squamous Cell Carcinoma: A Different Genomic Entity. (PubMed, Oral Maxillofac Surg Clin North Am)
    The tumor microenvironment is enriched with exhausted T cells, macrophages and cancer-associated fibroblasts. These insights support subsite-specific strategies incorporating targeted therapy, immunotherapy, chemoprevention, and saliva-based biomarkers for early detection, prognostication, surveillance, and improved clinical outcomes in GBMSCC.
    Review • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FAT1 (FAT atypical cadherin 1) • CASP8 (Caspase 8)
    |
    TP53 mutation • PIK3CA mutation
    2d
    From heterogeneity to molecular stratification: A multiplex genomic panel for tailored therapy of head and neck squamous cell carcinoma. (PubMed, Oral Oncol)
    Nevertheless, the prognostic value of selected genes should be established in wide genomic clinical trials, regarding drug response and overall survival rate (OSR). This article aims to elucidate the clinical utility of several genetic alterations towards a genetically informed prognostication and rationalized combination of novel targeted therapeutic tools.
    Journal
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NOTCH1 (Notch 1) • TNFA (Tumor Necrosis Factor-Alpha) • CDH1 (Cadherin 1) • FAT1 (FAT atypical cadherin 1)
    27d
    Biomass-Haze PM2.5 from Northern Thailand Drives Genotype-Specific Oxidative Stress and Transcriptomic Remodeling in Non-Small-Cell Lung Cancer Cells. (PubMed, Toxics)
    Pathway enrichment analyses highlighted oxidative stress, IL-17, NF-κB, and immune checkpoint signaling. Together, biomass haze-derived PM2.5 from Northern Thailand drives genotype-dependent oxidative stress and transcriptional remodeling in NSCLC cells.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FAT1 (FAT atypical cadherin 1) • GDF15 (Growth differentiation factor 15) • IL17A (Interleukin 17A) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1) • CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1) • TIPARP (TCDD Inducible Poly(ADP-Ribose) Polymerase)
    |
    KRAS mutation • EGFR mutation • PIK3CA mutation
    28d
    Genomic Profiling of Laryngeal Squamous Cell Carcinoma Reveals Novel Biomarkers for Precision Medicine. (PubMed, J Pers Med)
    These insights support development of targeted strategies, including immunotherapies such as pembrolizumab in TP53-altered tumors. These insights into the genomic heterogeneity of LSCC lay the groundwork for developing targeted therapeutic strategies and patient stratification, ultimately advancing a personalized medicine approach to this disease.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • NOTCH1 (Notch 1) • KMT2D (Lysine Methyltransferase 2D) • FAT1 (FAT atypical cadherin 1) • AVEN (Apoptosis And Caspase Activation Inhibitor)
    |
    TP53 mutation
    |
    Keytruda (pembrolizumab)
    1m
    Genetic Landscape of Oral Cavity Squamous Cell Carcinoma. (PubMed, OTO Open)
    A high tumor mutational burden (>10) is rare in oral cavity squamous cell carcinoma. Further research into the interplay between genetic mutations and patient outcomes is needed.
    Journal • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CDH1 (Cadherin 1) • FAT1 (FAT atypical cadherin 1) • TTN (Titin)
    |
    TP53 mutation • TMB-H • TP53 wild-type
    1m
    Divergent evolution of hepatocellular carcinoma genomes in chimpanzees and humans. (PubMed, Evol Med Public Health)
    Divergent evolutionary patterns highlight species-specific oncogenic routes while underscoring conserved pathways. Comparative primate cancer genomics offers novel insights into cancer evolution, biomarkers, and therapeutic targets.
    Journal • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ARID1A (AT-rich interaction domain 1A) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • TSC2 (TSC complex subunit 2) • FAT1 (FAT atypical cadherin 1) • VIM (Vimentin) • FAT4 (FAT Atypical Cadherin 4) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    TP53 mutation • TMB-H • ARID1A mutation
    2ms
    Immunophenotypic spectrum and mutational landscape of EBV-positive inflammatory follicular dendritic cell sarcoma. (PubMed, Histopathology)
    These findings demonstrate the wide morphological and immunophenotypic spectrum of EBV+ IFDCS. Furthermore, variants in chromatin modifier and HRR-related genes may participate in its pathogenesis, and PARP inhibition may represent a potential therapeutic strategy for patients with unresectable disease.
    Journal • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • FAT1 (FAT atypical cadherin 1) • FAT2 (FAT Atypical Cadherin 2)
    2ms
    Age- and Sex-Based Differences in the Genomic Profiles of Patients with Gastrointestinal and Pancreatic Neuroendocrine Neoplasms. (PubMed, Oncologist)
    Our study queries one of the largest datasets of GI- and P-NENs to date and highlights distinct age- and sex-specific molecular and immune profiles. Given the exploratory nature of these analyses and borderline significance, these results remain hypothesis-generating, providing an initial framework for future validation studies.
    Journal • MSi-H Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability) • RB1 (RB Transcriptional Corepressor 1) • TERT (Telomerase Reverse Transcriptase) • KMT2D (Lysine Methyltransferase 2D) • LAG3 (Lymphocyte Activating 3) • SMAD4 (SMAD family member 4) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • APC (APC Regulator Of WNT Signaling Pathway) • FAT1 (FAT atypical cadherin 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • MUTYH (MutY homolog) • CD80 (CD80 Molecule)
    |
    TP53 mutation • KRAS mutation • MSI-H/dMMR • PIK3CA mutation
    2ms
    Integrative analysis identifies PIGK as an oncogenic glycosylphosphatidylinositol transamidase subunit with prognostic, immunological, and therapeutic relevance in head and neck cancer. (PubMed, Int J Med Sci)
    PIGK functions as a potential oncogenic driver in HNC with prognostic and therapeutic relevance. Its association with FAM20C, taxane response, and modulation of fibroblast activation provides insights into PIGK-mediated oncogenesis and may inform patient stratification strategies.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NOTCH1 (Notch 1) • FAT1 (FAT atypical cadherin 1) • CASP8 (Caspase 8)
    |
    paclitaxel • docetaxel
    3ms
    New Gene Signature-Based Prognostic Model for Patients With VEGF-Overexpressing Esophageal Squamous Cell Carcinoma. (PubMed, Biomed Res Int)
    ESCC patients with FAT1, FGF3, FGF12, and FGF19 mutations; advanced M stage; and high neutrophil counts tended to have poorer prognoses. A model based on a four-gene signature effectively predicts the prognosis of ESCC patients.
    Journal • Gene Signature
    |
    VEGFA (Vascular endothelial growth factor A) • FGF19 (Fibroblast growth factor 19) • FGF3 (Fibroblast growth factor 3) • FAT1 (FAT atypical cadherin 1)
    3ms
    Loss of FAT1 drives cyclophosphamide resistance in breast cancer via the Wnt/β-Catenin pathway. (PubMed, Int J Biol Sci)
    Notably, combination therapy effectively alleviates drug resistance by suppressing the Wnt pathway. These findings highlight the critical role of FAT1 loss in mediating CTX resistance in BC and provide insights into potential therapeutic strategies targeting the Wnt pathway.
    Journal
    |
    CDH1 (Cadherin 1) • FAT1 (FAT atypical cadherin 1)
    |
    cyclophosphamide
    3ms
    Personalized ctDNA detection and genomic profiling in the NeoRHEA Study. (PubMed, NPJ Breast Cancer)
    We assessed ctDNA with the RaDaR assay in NeoRHEA (NCT03065621), a single-arm, phase II neoadjuvant palbociclib plus endocrine therapy trial over 4 months (4 × 28-day cycles)...Baseline ctDNA predicted poor response to this regimen, supporting ctDNA as a biomarker to guide treatment in HR + /HER2-negative disease. Trial registration: EU Clinical Trials Register (EudraCT 2016-000879-24; registered 15 February 2017).
    Journal • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FAT1 (FAT atypical cadherin 1)
    |
    HER-2 negative
    |
    RaDaR™ assay
    |
    Ibrance (palbociclib)